Related Experiment Video
Updated: Feb 14, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with
Jun Ho Yi1, Silvia Park2, Jung Han Kim3
1Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea.
Insights
Decitabine shows promise as a first-line treatment for elderly acute myeloid leukemia (AML) patients in Korea. This study found improved outcomes in Korean AML patients treated with decitabine.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Decitabine is a standard treatment for elderly acute myeloid leukemia (AML).
- Its efficacy in Asian populations, specifically Koreans, remains under-evaluated.
Purpose of the Study:
- To assess the clinical outcomes of decitabine treatment in elderly Korean AML patients.
- To evaluate decitabine as a potential first-line therapy for this demographic.
Main Methods:
- Retrospective analysis of 80 Korean elderly AML patients treated with decitabine.
- Data collected included patient age, risk stratification (favorable, intermediate, poor), and overall survival (OS).
Main Results:
- The median age of patients was 74 years.
- Patients were stratified into favorable (7.5%), intermediate (60.0%), and poor (31.3%) risk groups.
- The median overall survival (OS) was 10.2 months (95% CI 5.0-15.4).
Conclusions:
- Decitabine treatment demonstrated improved clinical outcomes in the studied Korean elderly AML cohort.
- Decitabine can be considered a viable first-line treatment option for elderly Korean patients with AML.
Abstract:
Decitabine is widely accepted as the treatment options for elderly acute myeloid leukemia (AML) patients. However, the efficacy has yet been assessed in Asian population. We retrospectively analyzed the outcomes of 80 Korean elderly AML patients who were treated with decitabine. The median age was 74 years (range, 64 to 86 years) and 6 (7.5%), 48 (60.0%), and 25 (31.3%) patients were categorized to favorable, intermediate, and poor risk group, respectively. The median OS was 10.2 months (95% CI 5.0-15.4). Given that decitabine treatment demonstrated improved clinical outcomes, it could be considered as one of the first-line treatment for Korean elderly AML patients.
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute Pyelonephritis I: Introduction
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:

